<DOC>
	<DOCNO>NCT01921673</DOCNO>
	<brief_summary>Docetaxel currently one standard second-line therapy patient gastric cancer . As angiogenesis FGFR pathway suggest associated gastric cancer , dovitinib , dual VEGFR FGFR inhibitor , may potential improve outcome patient gastric cancer . Therefore , investigated combination regimen docetaxel dovitinib .</brief_summary>
	<brief_title>Dovitinib Plus Docetaxel Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Pathologically proven metastatic unresectable adenocarcinoma stomach gastroesophageal junction 2 . Patients progressive disease ( radiological confirmation require ) one line chemotherapy except taxane advance gastric cancer palliative set 3 . Presence least one evaluable disease Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 4 . Age 18 74 year 5 . Estimated life expectancy 3 month 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0~2 7 . Adequate bone marrow function ( Absolute neutrophil count ≥ 1,500/uL , hemoglobin ≥ 8.0g/dL , platelet ≥ 100,000/uL ) 8 . Adequate renal function ( creatinine &lt; 1.5mg/dL ) 9 . Adequate hepatic function ( total bilirubin &lt; 1.5 mg/dL , transaminase &lt; 3 time upper normal limit [ 5 time patient liver metastasis ] ) 10 . No prior antiangiogenic therapy ( antiVEGF VEGFR tyrosine kinase inhibitor etc ) FGF/FGFR inhibitor 11 . No prior radiation therapy within 4 week study ( Irradiated lesion include evaluable lesion . ) 12 . Written inform consent 1 . Past concurrent history neoplasm gastric adenocarcinoma , except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri 2 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start 3 . Bowel obstruction 4 . Evidence serious gastrointestinal bleeding 5 . Presence central nervous system ( CNS ) metastasis 6 . History significant neurologic psychiatric disorder 7 . Significant cardiac disease within 6 month study ( congestive heart failure uncontrollable medication , symptomatic coronary heart disease , arrhythmia , myocardial infarction ) 8 . Left ventricular ejection fraction ( LVEF ) assess 2D echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) , &lt; 45 % 9 . Uncontrolled hypertension define SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg , without antihypertensive medication . Initiation adjustment antihypertensive medication ( ) allow prior study entry . 10 . QTc &gt; 480 msec screen ECG 11 . Proteinuria define NCI CTCAE grade &gt; 1 baseline measure urine dipstick ( 2+ great ) confirm 24 hour urine collection ( &gt; 1g/24hrs ) . Subjects may rescreened blood pressure show control without intervention 12 . History thrombotic bleeding diathesis coagulopathy 13 . Serious nonhealing wound , peptic ulcer , bone fracture 14 . Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month 15 . Pregnant lactate woman , woman childbearing potential employ adequate contraception 16 . Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>Second-line chemotherapy</keyword>
	<keyword>Dovitinib</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Refractory first-line chemotherapy</keyword>
</DOC>